BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

862 related articles for article (PubMed ID: 11044354)

  • 1. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group.
    Anglian Breast Cancer Study Group
    Br J Cancer; 2000 Nov; 83(10):1301-8. PubMed ID: 11044354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study.
    Antoniou AC; Pharoah PD; McMullan G; Day NE; Ponder BA; Easton D
    Genet Epidemiol; 2001 Jul; 21(1):1-18. PubMed ID: 11443730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.
    Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Kwan E; Jack E; Vesprini DJ; Kuperstein G; Abrahamson JL; Fan I; Wong B; Narod SA
    Am J Hum Genet; 2001 Mar; 68(3):700-10. PubMed ID: 11179017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer.
    Peto J; Collins N; Barfoot R; Seal S; Warren W; Rahman N; Easton DF; Evans C; Deacon J; Stratton MR
    J Natl Cancer Inst; 1999 Jun; 91(11):943-9. PubMed ID: 10359546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study.
    Hopper JL; Southey MC; Dite GS; Jolley DJ; Giles GG; McCredie MR; Easton DF; Venter DJ
    Cancer Epidemiol Biomarkers Prev; 1999 Sep; 8(9):741-7. PubMed ID: 10498392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1 and BRCA2 mutation status and cancer family history of Danish women affected with multifocal or bilateral breast cancer at a young age.
    Bergthorsson JT; Ejlertsen B; Olsen JH; Borg A; Nielsen KV; Barkardottir RB; Klausen S; Mouridsen HT; Winther K; Fenger K; Niebuhr A; Harboe TL; Niebuhr E
    J Med Genet; 2001 Jun; 38(6):361-8. PubMed ID: 11389159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer.
    Moslehi R; Chu W; Karlan B; Fishman D; Risch H; Fields A; Smotkin D; Ben-David Y; Rosenblatt J; Russo D; Schwartz P; Tung N; Warner E; Rosen B; Friedman J; Brunet JS; Narod SA
    Am J Hum Genet; 2000 Apr; 66(4):1259-72. PubMed ID: 10739756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families.
    Levy-Lahad E; Catane R; Eisenberg S; Kaufman B; Hornreich G; Lishinsky E; Shohat M; Weber BL; Beller U; Lahad A; Halle D
    Am J Hum Genet; 1997 May; 60(5):1059-67. PubMed ID: 9150153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hereditary susceptibility to breast cancer: significance of age of onset in family history and contribution of BRCA1 and BRCA2.
    Frank TS; Deffenbaugh AM; Hulick M; Gumpper K
    Dis Markers; 1999 Oct; 15(1-3):89-92. PubMed ID: 10595259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic.
    Martin AM; Blackwood MA; Antin-Ozerkis D; Shih HA; Calzone K; Colligon TA; Seal S; Collins N; Stratton MR; Weber BL; Nathanson KL
    J Clin Oncol; 2001 Apr; 19(8):2247-53. PubMed ID: 11304778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer.
    Loman N; Johannsson O; Kristoffersson U; Olsson H; Borg A
    J Natl Cancer Inst; 2001 Aug; 93(16):1215-23. PubMed ID: 11504767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases.
    Malone KE; Daling JR; Neal C; Suter NM; O'Brien C; Cushing-Haugen K; Jonasdottir TJ; Thompson JD; Ostrander EA
    Cancer; 2000 Mar; 88(6):1393-402. PubMed ID: 10717622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Offit K; Foulkes W; Robson ME; Wacholder S; Eng CM; Karp SE; Begg CB
    Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):467-73. PubMed ID: 11352856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.
    Ford D; Easton DF; Stratton M; Narod S; Goldgar D; Devilee P; Bishop DT; Weber B; Lenoir G; Chang-Claude J; Sobol H; Teare MD; Struewing J; Arason A; Scherneck S; Peto J; Rebbeck TR; Tonin P; Neuhausen S; Barkardottir R; Eyfjord J; Lynch H; Ponder BA; Gayther SA; Zelada-Hedman M
    Am J Hum Genet; 1998 Mar; 62(3):676-89. PubMed ID: 9497246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
    Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
    Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
    van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
    Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRCA1 and BRCA2 mutations among Finnish ovarian carcinoma families.
    Sarantaus L; Auranen A; Nevanlinna H
    Int J Oncol; 2001 Apr; 18(4):831-5. PubMed ID: 11251181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers.
    Kadouri L; Easton DF; Edwards S; Hubert A; Kote-Jarai Z; Glaser B; Durocher F; Abeliovich D; Peretz T; Eeles RA
    Br J Cancer; 2001 Jul; 85(1):36-40. PubMed ID: 11437399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
    Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
    Antoniou A; Pharoah PD; Narod S; Risch HA; Eyfjord JE; Hopper JL; Loman N; Olsson H; Johannsson O; Borg A; Pasini B; Radice P; Manoukian S; Eccles DM; Tang N; Olah E; Anton-Culver H; Warner E; Lubinski J; Gronwald J; Gorski B; Tulinius H; Thorlacius S; Eerola H; Nevanlinna H; Syrjäkoski K; Kallioniemi OP; Thompson D; Evans C; Peto J; Lalloo F; Evans DG; Easton DF
    Am J Hum Genet; 2003 May; 72(5):1117-30. PubMed ID: 12677558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.